VISTA: A Target to Manage the Innate Cytokine Storm
Autor: | Mohamed A. ElTanbouly, Yanding Zhao, Evelien Schaafsma, Christopher M. Burns, Rodwell Mabaera, Chao Cheng, Randolph J. Noelle |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
CD4-Positive T-Lymphocytes
lcsh:Immunologic diseases. Allergy 0301 basic medicine B7 Antigens Myeloid medicine.medical_treatment T cell Antigen presentation Immunology Lipopolysaccharide Receptors Biology GPI-Linked Proteins Lymphocyte Activation Mice 03 medical and health sciences 0302 clinical medicine Immune system medicine Animals Humans Immunology and Allergy Myeloid Cells immune checkpoint Antigen Presentation immunosuppression SARS-CoV-2 Receptors IgG COVID-19 monocyte reprogramming Immunotherapy medicine.disease Immune checkpoint agonistic antibodies 030104 developmental biology medicine.anatomical_structure Cytokine Perspective Interferon Type I cytokine storm vista myeloid Cytokine Release Syndrome lcsh:RC581-607 Cytokine storm 030215 immunology |
Zdroj: | Frontiers in Immunology, Vol 11 (2021) Frontiers in Immunology |
ISSN: | 1664-3224 |
DOI: | 10.3389/fimmu.2020.595950 |
Popis: | In recent years, the success of immunotherapy targeting immunoregulatory receptors (immune checkpoints) in cancer have generated enthusiastic support to target these receptors in a wide range of other immune related diseases. While the overwhelming focus has been on blockade of these inhibitory pathways to augment immunity, agonistic triggering via these receptors offers the promise of dampening pathogenic inflammatory responses. V-domain Ig suppressor of T cell activation (VISTA) has emerged as an immunoregulatory receptor with constitutive expression on both the T cell and myeloid compartments, and whose agonistic targeting has proven a unique avenue relative to other checkpoint pathways to suppress pathologies mediated by the innate arm of the immune system. VISTA agonistic targeting profoundly changes the phenotype of human monocytes towards an anti-inflammatory cell state, as highlighted by striking suppression of the canonical markers CD14 and Fcγr3a (CD16), and the almost complete suppression of both the interferon I (IFN-I) and antigen presentation pathways. The insights from these very recent studies highlight the impact of VISTA agonistic targeting of myeloid cells, and its potential therapeutic implications in the settings of hyperinflammatory responses such as cytokine storms, driven by dysregulated immune responses to viral infections (with a focus on COVID-19) and autoimmune diseases. Collectively, these findings suggest that the VISTA pathway plays a conserved, non-redundant role in myeloid cell function. |
Databáze: | OpenAIRE |
Externí odkaz: |